Involved-Field Radiotherapy prevents recurrences in the early stages of Hodgkin's lymphoma in PET-negative patients after ABVD Chemotherapy Relapse Analysis of GHSG Phase III HD16 Trial

The HD16 trial of the GHSG (xxxxxxxx) demonstrated that radiotherapy in early-stage Hodgkin's lymphoma without risk factors (ESHL) cannot be safely omitted and therefore combined modality therapy (CMT) remains the standard treatment. To demonstrate the local effect of consolidating involved-field radiotherapy (IF-RT) we performed an analysis of the recurrence pattern of PET-negative HD16 patients.

Source: International Journal of Radiation Oncology * Biology * Physics - August 10, 2021 Category: Radiology Authors: Christian Baues, Helen Goergen, Michael Fuchs, Dr. Johannes Rosenbrock, Eren Celik, Hans Eich, Carsten Kobe, Conrad-Amadeus Voltin, Andreas Engert, Peter Borchmann, Simone Marnitz Tags: Clinical Investigation Source Type: research